The project Tankyrase Inhibition in Cancer Immunotherapy aims to bring the proprietary clinical candidate tankyrase inhibitor OM-153 towards commercialization. The commercialization is done together with the Dutch medicinal chemistry company Merchachem and Inven2.
- This grant allows us to continue and finalize essential basic and translational research to reach our goal of getting the drug into clinical studies, says Jo Waaler.
- At current there is no WNT inhibitor in clinical practice. We have been working for the last 10 years to build up an internationally leading drug discovery program that addresses WNT signaling. We are very happy about the continued support by the health region to further advance the clinical candidate stage compound towards patients, says Stefan Krauss